*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity The Journal of pharmacology and experimental therapeutics · preclinical | PMID 41421047 |
| 2026 | Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling International journal of biological macromolecules · preclinical | PMID 41850449 |
| 2024 | A Synthetic ERR Agonist Alleviates Metabolic Syndrome The Journal of pharmacology and experimental therapeutics · preclinical | PMID 37739806 |
| 2024 | Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function Circulation · preclinical | PMID 37961903 |
| 2023 | Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity ACS chemical biology · preclinical | PMID 36988910 |
| 2023 | Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney The American journal of pathology · preclinical | PMID 37717940 |
SLU-PP-332 (SLU-PP-332 (pan-ERR agonist; 'exercise mimetic')). Small-molecule pan-agonist of estrogen-related receptors (ERR) — not a peptide. Preclinically upregulates mitochondrial biogenesis and oxidative metabolism, mimicking endurance-exercise adaptations in mice.
Commonly discussed uses: exercise-mimetic / metabolic research (preclinical). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Small-molecule pan-agonist of estrogen-related receptors (ERR) — not a peptide. Preclinically upregulates mitochondrial biogenesis and oxidative metabolism, mimicking endurance-exercise adaptations in mice.
Reported considerations: no human safety data. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical small molecule (not a peptide). No human data. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose, high unknown. Administration: oral/injection (animal studies). Half-life: not characterised in humans.
Australian status: Not ARTG-registered; research. Preclinical small molecule (not a peptide). No human data. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: per product.
Commonly discussed combinations (anecdotal for unapproved compounds): experimental; no protocols. Stacking increases interaction/safety uncertainty.